Theravance Biopharma, Inc. (TBPH)

NGM – Real vaqt narxi. Valyuta: USD

16.48

-0.04 (-0.24%)

Yopilishda: May 12, 2026, 4:00 PM EDT

08.05.2026

TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle

Theravance Q1 earnings top estimates as collaboration revenues grow, while restructuring and cost cuts aim to drive $60-$70M annualized cash flow.

07.05.2026

Here's Why Theravance Biopharma (TBPH) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

07.05.2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ: TBPH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

07.05.2026

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

YUPELRI ® Collaboration Revenue increased 15% year-over-year 1 , from $15.4 million to $17.7 million, driven by continued Net Sales growth and improved operating leverage All Hatch-Waxman litigation relating to YUPELRI ® has been resolved following settlement with Mankind Pharma in March Organizational restructuring and cost reduction initiatives on track; delivered ~20% reduction in Operating Expenses year-over-year (excluding restructuring items) Q1 2026 TRELEGY net sales, reported by GSK, of $873 million, up 2% year-over-year; high confidence in achieving the $100 million 2026 milestone payment 2 Strategic Review Committee actively evaluating a range of opportunities to maximize shareholder value Quarter-end cash balance of $395 million and no debt DUBLIN, May 7, 2026 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the first quarter of 2026. "We delivered strong financial performance in the first quarter, reinforcing the quality of our commercial asset, our robust balance sheet and the important actions underway to reshape our cost structure, following the outcome of the CYPRESS study," said Rick E Winningham, Chief Executive Officer of Theravance Biopharma.

01.05.2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ: TBPH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

28.04.2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. (“Theravance” or the “Company”) (NASDAQ: TBPH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

21.04.2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. (“Theravance” or the “Company”) (NASDAQ: TBPH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Videolar

No Data

There is no data to display

Press-relizlar

07.05.2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

07.05.2026

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

01.05.2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

28.04.2026

Theravance Biopharma, Inc. (TBPH)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Theravance Biopharma, Inc. (TBPH)

TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle

Here's Why Theravance Biopharma (TBPH) is a Strong Momentum Stock

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

Videolar

No Data

Press-relizlar

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle

Here's Why Theravance Biopharma (TBPH) is a Strong Momentum Stock

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

Videolar

No Data

Press-relizlar

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

Search stocks

Theravance Biopharma, Inc. (TBPH)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Theravance Biopharma, Inc. (TBPH)

TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle

Here's Why Theravance Biopharma (TBPH) is a Strong Momentum Stock

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

Videolar

No Data

Press-relizlar

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle

Here's Why Theravance Biopharma (TBPH) is a Strong Momentum Stock

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

Videolar

No Data

Press-relizlar

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH